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Introduction and literature review        
Primary mucosal sinonasal melanoma accounts for 0.5-2% of all melanomas, 4% of head and 
neck melanomas and 4-8% of all sinonasal malignancies.1-7  They have an equal gender 
distribution and usually occur in patients in their  6th-7th decade of life.8 Sinonasal melanomas 
are rare, aggressive tumours often associated with a poor prognosis due to advanced stage 
disease at presentation. Regional and distant metastases are present at presentation in a third 
of cases.7 Mean 5-year survival is 0-46%.9 The vast majority (80%) arise from the nasal vault 
(lateral nasal wall and nasal septum). The remainder are of sinus origin, with the maxillary sinus 
most commonly involved.10 Those arising from the nasal vault have a better prognosis and 5-
year survival.11  
 
Epidemiology 
Interestingly, the incidence of mucosal melanoma is higher in areas where the incidence of 
cutaneous melanoma is lower. Both variants occur more commonly in Caucasian populations, 
although 7% of mucosal melanomas occur in Afro-Caribbean populations compared to just 0.8% 
of cutaneous melanomas.12-14  The incidence of mucosal melanoma has remained relatively 
constant, while that of cutaneous melanoma has risen on average 1.4% per year over the last 
decade in the United States of America (USA).15  
 
Aetiology 
Melanomas arise from melanocytes, a derivative of neural crest cells, which migrate to the site 
of origin during embryogenesis.16, 12 Risk factors for sinonasal melanoma remain unclear, 
although pre-existing mucosal melanosis has been linked to oral mucosal melanoma.18 An 
association with sinonasal melanoma has yet to be demonstrated. Various authors have 
suggested that occupational exposure to formaldehyde (present in paints, adhesives, 
cosmetics, textiles and tobacco smoke) is a possible risk factor.11, 19-21  Ultraviolet A (UVA) and 
ultraviolet B (UVB) radiation play an integral role in the pathogenesis of most cutaneous 
melanomas through a variety of mechanisms, including direct melanocyte DNA damage or 
stimulation of melanocyte cell division, suppression of cutaneous immunity and free radical 
synthesis.  
 
Roughly 40% of melanomas exhibit activating mutations responsible for structural changes in 
the B-Raf protein, responsible for intracellular cell signaling and ultimately cell division and 
differentiation. A number of gene mutations (CDKN2A, RB1, CDK4, BRAF, KIT, NRAS) have been 
implicated in both the sporadic and hereditary variants of melanoma. The frequency of 
different gene mutations varies between cutaneous and sinonasal melanoma, and site of 
melanoma.22-26 Those mutations linked to UV radiation occur less frequently in the sinonasal 
variant, supporting the distinct nature and aetiology of sinonasal melanomas (which is unlikely 
to be related to sun exposure). 
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Clinical presentation 
Patients with sinonasal melanoma are often asymptomatic in the initial stages of the disease. 
However, with tumour growth, presenting complaints include unilateral or bilateral nasal 
obstruction, epistaxis, rhinorrhoea, hyposmia, epiphora, frontal headaches and facial pain. 
Proptosis and ophthalmoplegia with diplopia signal orbital involvement. These are late 
symptoms with an average delay in presentation varying from 1 month to two years.27 Mucosal 
lesions are usually pigmented, although non-pigmented, amelanotic melanomas are also 
possible. Independent clinical predictors of poorer survival include advanced patient age, large 
tumours and the nodal status or presence of distant metastases at diagnosis.28-29 
 
Diagnosis  
Thorough history taking and clinical examination are important in the workup of sinonasal 
masses. The macroscopic appearance of sinonasal melanoma on anterior rhinoscopy or 
nasendoscopy varies from classical bluish-black mucosal lesions, to pale yellow or translucent 
polypoid masses in the amelanotic variant.30 Identifying the primary site often proves difficult 
as disease is usually widespread, sometimes with satellite lesions. Nodal assessment for 
regional disease (10-50% at presentation)31-32 and workup for distant metastases (40-76% at 
presentation33-34) are also important considerations. Thorough dermatological assessment for 
skin metastases is also required.31 
 
Histopathology, with immunohistochemistry, is the gold standard in confirming the diagnosis of 
sinonasal melanoma. Diagnosis, based on histopathology alone, can prove difficult and is prone 
to error.31 Following histological confirmation of melanoma, various imaging modalities are 
employed to stage the disease. Computed tomography (CT) scanning usually demonstrates a 
soft tissue mass, with or without associated bony erosion. Magnetic resonance imaging (MRI) is 
useful in assessing tumour bulk and extent, especially orbital and intracranial involvement, as 
well as to differentiate between tumour mass and fluid/secretions within the sinuses.  Positron 
emission tomography (PET) scanning is a useful adjunct in assessing for distant metastases and 
local recurrence.11 
 
Independent predictors of poor survival on histology of sinonasal melanoma include: 
• Vascular invasion  
• Necrosis 
• Polymorphous tumour cell population 
 
Histological features of little prognostic significance in sinonasal melanoma (unlike cutaneous 
melanoma) include:35-36 
 
• Tumour thickness 
• Level of invasion 
• Ulceration 
• Mitotic index 
• Nerve involvement 
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Staging 
In 1970, Ballantyne37 described 3 stages of mucosal melanoma of the head and neck, based on 
tumour spread: 
• Stage I   Local; confined to the primary site 
• Stage II  Regional; regional lymph node involvement 
• Stage III  Disseminated; systemic metastases 
 
The disadvantage of this staging system was that the extent of local disease and depth of 
invasion was not quantified. To overcome these shortcomings, Parsad et al.38 modified the 
Ballantyne staging system in 2004 to include 3 subgroups of stage I disease, taking depth of 
invasion into account: 
• Level I Melanoma in situ or microinvasion 
• Level II  Invasion of lamina propria only 
• Level III  Deep tissue invasion 
 
This sub-classification never gained universal acceptance and failed to correlate with prognosis 
in various studies.39 
 
The American Joint Committee on Cancer (AJCC) published a TNM staging system for mucosal 
melanoma in 2002, revised in 2009, to reflect the aggressive behaviour of these tumours. The 
2009 system, proposed by Patel and Shah40, is a specific classification for mucosal melanoma of 
the head and neck and depends on tumour size and extent. If the mucosal lesion is identified 
clinically, tumour stage will be at least T3. As such, T1 and T2 tumours cannot be identified 
clinically. 
 
TNM staging system for sinonasal melanoma (2009): 
Primary Tumour (T) 
• Tx: Primary tumour cannot be evaluated 
• T3: Disease restricted to mucosa 
• T4a: Moderately advanced disease: tumour involving soft tissue, cartilage, bone, 
overlying skin 
• T4b: Very advanced disease: tumour involving brain, dura mater, skull base, cranial 
nerves (IX, X, XI, and XII), masticator space, carotid artery, prevertebral space, or 
mediastinal structure 
Regional Lymph Nodes (N) 
• Nx: Regional lymph nodes cannot be evaluated 
• N0: No evidence of regional nodal metastases 
• N1: Regional nodal metastases 
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Distant Metastases (M) 
• M0: No distant metastases 
• M1: Distant metastases 
In 2016, Houette et al.41 compared the prognostic value of the 2002 and 2009 TNM staging 
systems. The 2009 staging system allows for more homogenous patient groups and clearly 
distinguishes moderately advanced T3 disease from very advanced T4 disease, with a very poor 
prognosis. The non-specific AJCC 2002 Clinical Staging Manual has better prognostic value and 
the authors conclude that this system should not be abandoned.  
 
 
Treatment options 
Various modalities are employed in the management of sinonasal melanoma. Surgery is 
regarded as the primary treatment modality42, but the roles of neck dissection, adjuvant 
radiotherapy and chemotherapy remain controversial.  
 
Surgery 
The goal of surgery in sinonasal melanoma is local tumour resection with wide margins. Despite 
aggressive surgery, local recurrence occurs in 29-79% of patients.43-48 Complete resection is a 
surgical challenge and it is often impossible to achieve adequate margins due to tumour extent 
and the fact that tumour often abuts vital anatomical structures. Incomplete resection has been 
shown to be a predictor of poor survival.49-50-29 Surgical resection is occasionally considered 
following a course of neo-adjuvant radiation therapy or chemotherapy, when the tumour has 
more favourable dimensions and surgery is more likely to achieve adequate surgical margins.  
 
Surgical options for local control include51: 
▪ Endoscopic resection without dural excision 
▪ Endoscopic resection with transnasal craniectomy 
▪ Combined cranio-endoscopic resection 
▪ Trans-facial external approaches 
 
Outcome after endoscopic resection has been found to be comparable or better than the more 
aggressive external craniofacial approaches.  The most important surgical prognostic factor is 
the presence of clear surgical margins.52 
 
In the N0 neck, prophylactic neck dissection is not indicated as the incidence of occult nodal 
metastasis is low (<10%). However, regional lymph node metastasis is associated with very high 
mortality rate.53  
 
Konuthula et al. analysed the outcomes of patients with sinonasal melanoma registered on the 
American National Cancer Data Base (NCDB). In their analysis of 695 patients between 2004 and 
2010, they found no statistically significant difference in 5-year survival between those 
managed with neck dissection and those managed without.29 
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External Beam Radiotherapy (EBRT) 
Historically, sinonasal melanoma was regarded as a radio-resistant tumour. Recently, however, 
studies have suggested that radiotherapy may improve local control, with little effect on overall 
survival.  No randomised controlled trial has been done in this regard. 7,53-55  
 
Chemotherapy 
Unlike cutaneous melanoma, sinonasal melanoma has a poor response to systemic treatment 
with either chemotherapy (mainly cisplatin and actinomycin D) or biochemotherapy (based on 
a biotherapeutic agent e.g. interferon, interleukin-2). Biochemotherapy may be useful in the 
adjuvant setting. Chemotherapy is most commonly used in the setting of palliative treatment or 
in cases where surgery is contraindicated.56-57 
 
Brachytherapy 
To our knowledge, Harris, et al.58 were the first to report on the use of post-operative 
brachytherapy to prevent local recurrence after endoscopic resection of sinonasal melanoma.  
A special applicator was designed to fit the nasal cavity and was inserted into the nasal cavity 
under general anaesthesia, delivering 60 Gy radiation dose over 5 days (a similar dose delivered 
via intensity-modulated radiation therapy is usually delivered over a period of 6 weeks). Their 
patient was a 46-year-old female with pT4 sinonasal melanoma (AJCC 2009) who underwent 
endoscopic tumour resection at the authors’ institution. Intra-operatively, she was noted to 
have possible microscopic disease left on the dura. She received postoperative brachytherapy 
to treat the dura in the region of the involved cribriform plate. After 13 years of follow up at our 
institution, repeat PET scan showed no local recurrence or distant metastases.  
 
Basel Al Kadah et al.59 published their experience with silicone brachytherapy applicators in 20 
patients (January 2001-January 2013) with different sinonasal and nasopharyngeal cancers after 
endoscopic tumour resection. One patient in the study had mucosal melanoma. Tumour control 
was achieved in 13 patients, seven patients experienced local recurrence and the overall 2-year 
survival was 57.3%. Their recommendation was that larger patient numbers were required to 
assess the efficacy of this method.  
 
Nikolaos Tselis et al.60 published their experience in treating four cases of inoperable, recurrent 
head and neck cancer with CT-guided interstitial high-dose rate brachytherapy. This included 
one patient with sinonasal melanoma, a 52-year-old male with T3N0M0 (AJCC 2009) disease. 
Initially treated with maxillofacial resection and adjuvant immunotherapy, he developed 
irresectable local recurrence after 4 months and was treated with chemoradiotherapy. Despite 
this, he presented with disease progression after six months. This patient then received 
brachytherapy and local control was achieved for a total of 31 months thereafter.  
 
 
Justification 
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The potential benefit of brachytherapy following endoscopic sinonasal tumour resection should 
be explored. If adjuvant brachytherapy is found to offer survival benefit in sinonasal melanoma, 
it could expand the current treatment armamentarium and be incorporated into treatment 
regimens.  
Our retrospective study aims to reveal how this technique could potentially: 
• Prevent local tumour recurrence  
• Improve local control and overall survival  
• Minimize duration of treatment (as compared to external beam radiation therapy) 
• Lower complication rate 
 
Aims 
This study aims to evaluate the use of brachytherapy after endoscopic resection of sinonasal 
malignant mucosal melanomas. The primary outcome is to determine local tumour control  
rates and overall survival. A survival analysis will be performed using the Kaplan–Meier method 
with Greenwood formula for standard error.  
Secondary outcomes are to explore the side effects and risks of sinonasal brachytherapy, 
including the effect of brachytherapy on surrounding anatomical structures. 
 
Research design and methods: 
An eleven-year retrospective analysis of all sinonasal malignant melanomas (2004-2015) 
managed with endoscopic resection and adjuvant brachytherapy, by a single surgeon (Prof D 
Lubbe), in both her state and private practices will be carried out. Patients will be identified 
from departmental records and oncology databases. A minimum duration of follow up of two 
years will be required. All patient lost to follow up will be contacted.  
The following data will be collected and analysed: 
• Patient age  
• Patient gender  
• Details of clinical presentation   
• Tumour imaging 
• Tumour staging  
• Treatment received (type and duration) 
• Complications following treatment 
o Immediate/acute 
▪ General: fatigue, nausea and vomiting, diarrhoea 
▪ Pain 
▪ Local tissue toxicity: swelling, inflammation, haemorrhage, sloughing 
o Delayed/long term 
▪ Tissue fibrosis/necrosis 
▪ Second primary malignancy 
• Follow up (clinical and imaging) 
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• Local control rate will be assessed clinically and with imaging; overall survival will be 
calculated  
 
Inclusion criteria  
• Patients with sinonasal malignant melanoma managed with endoscopic resection and 
adjuvant brachytherapy between 2004 and 2015 
• Minimum of 2 years follow up following completion of brachytherapy regimen 
• Patients >18 years of age 
• Adequate record keeping 
 
Exclusion criteria 
• Patients <18 years of age 
• Patients lost to follow up 
• Inadequate record keeping 
• Patients unable to complete the prescribed brachytherapy dose/duration 
 
Outcomes: 
This paper will be one of the largest published series on sinonasal mucosal melanoma in the 
present literature. With the addition of brachytherapy to the treatment regimen, we will 
investigate whether or not local tumour control rate and overall survival is better than that 
described for other treatment modalities. The role of brachytherapy has not been investigated 
in the treatment of sinonasal mucosal melanoma but may represent an important addition to 
current practice. 
 
Privacy and confidentiality: 
Only the principal investigator and study supervisor will have access to patient medical records 
for the purposes of data collection. Data will be recorded on an electronic data sheet on a 
computer that is password protected. Strict confidentiality will be maintained. No patient 
names will be divulged and no patient identifiers will be visible in any of the images used. 
 
Risks and benefits: 
Patients enrolled in the study will incur no risk or benefit. Knowledge gained from this research 
may benefit others in the future.  
 
 
 
 
 
 
 
Ethical considerations: 
 10 
Ethics approval will be sought from the University of Cape Town Human Research Ethics 
Committee.  
Autonomy 
Not applicable in this study. 
Beneficence 
Should this study demonstrate benefit of brachytherapy in the management of sinonasal 
melanoma, this modality could be offered to other patients and improve local control rates and 
survival. 
Non-maleficence 
No potential harm to study population. 
Justice 
All patients meeting the inclusion criteria will be included in the study, the results of which will 
be dispersed within the medical fraternity locally and internationally, ensuring distributive 
justice. 
 
Informed consent: 
This is not necessary due to the retrospective nature of the study. 
 
Timeline: 
The anticipated data collection duration is three months. 
 
Stakeholder and reporting: 
The results of the study will be reported back to the Division of Otolaryngology at Groote 
Schuur Hospital as a formal report. It will also form part of an MMED study and submitted for 
publication in a reputable journal. 
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Endoscopic Resection and Post-Operative Brachytherapy in the Treatment of 
Sinonasal Melanoma 
 
Abstract  
    Background: Sino-Nasal Melanomas (SNM) are rare, aggressive tumours often associated with a poor 
prognosis due to advanced stage disease at presentation. Mean 5-year survival is 0-46%. 
Various treatment modalities are used in the management of SNM. Surgery is regarded as the 
primary treatment modality, but therapy remains controversial. Complete resection is a surgical 
challenge and it is often impossible to achieve adequate margins due to the fact that tumour 
often abuts vital anatomical structures. Incomplete resection has been shown to be a predictor 
of poor survival. Harris et al. (2014) were the first to report on the use of post-operative brachytherapy 
in an attempt to prevent local recurrence after endoscopic resection of SNM. 
 
    Methods: A retrospective analysis of all patients undergoing endoscopic resection of SNMs and 
receiving adjuvant brachytherapy in a single surgeon’s practice between August 2004 and May 2014 was 
carried out. Outcome measures included local control rate and 5-year overall survival estimated by 
Kaplan-Meier analysis. The incidence of regional and distal recurrence (metastases) was calculated 
    Results: Five cases of sinonasal melanoma (3 males 2, females) were managed with endoscopic 
resection and adjuvant brachytherapy. Patients were followed up for a median duration of 61 months 
(32-154 months) following adjuvant Brachytherapy. Local control was achieved in four out of five 
patients (80%). Three out of five patients developed distant metastasis. Median time to metastasis was 
54 months. One patient received immunotherapy after diagnosis of distant metastasis (BRAF positive). 
Three out of five patients (60%) died from the complications of distant metastases of sinonasal 
melanoma. Median survival time following adjuvant Brachytherapy was 61 months (32-154 months). 
Five-year survival rate was 40% (95% CI 5.2% - 75.3%). 
    Conclusion: This is the only case series describing the use of brachytherapy following endoscopic 
resection of sinonasal melanoma. Our case series, albeit small, describes a local control rate and 5-year 
survival comparable with the best reported in the literature. Adjuvant brachytherapy represents a novel 
approach and potentially a useful addition to the adjuvant therapy armamentarium. The advantages of 
brachytherapy include a favourable side-effect profile and a shorter duration of treatment, while 
delivering a dose of radiation similar to that of Conventional Radiotherapy. Further studies are 
necessary to define the role of brachytherapy in sinonasal melanoma. 
 
 
 
 
 
 
Introduction  
Primary mucosal sinonasal melanoma accounts for 0.5-2% of all melanomas, 4% of head and neck 
melanomas and 4-8% of all sinonasal malignancies.1-7  They have an equal gender distribution and 
usually occur in patients in their  6th-7th decade of life.8 Sinonasal melanomas are rare, aggressive 
tumours often associated with a poor prognosis due to advanced stage disease at presentation. Regional 
and distant metastases are present at presentation in a third of cases. 7 Mean 5-year survival is 0-46%.9 
The vast majority (80%) arise from the nasal vault (lateral nasal wall and nasal septum). The remainder 
are of sinus origin, with the maxillary sinus most commonly involved.10 Those arising from the nasal 
vault have a better prognosis and 5-year survival.11  
Interestingly, the incidence of mucosal melanoma is higher in areas where the incidence of cutaneous 
melanoma is lower. Both variants occur more commonly in Caucasian populations, although 7% of 
mucosal melanomas occur in Afro-Caribbean populations compared to just 0.8% of cutaneous 
melanomas.12-14  The incidence of mucosal melanoma has remained relatively constant, while that of 
cutaneous melanoma has risen on average 1.4% per year over the last decade in the United States of 
America (USA).15  
Melanomas arise from melanocytes, a derivative of neural crest cells, which migrate to the site of origin 
during embryogenesis12,16 Risk factors for sinonasal melanoma remain unclear, although pre-existing 
mucosal melanosis has been linked to oral mucosal melanoma.17 An association with sinonasal 
melanoma has yet to be demonstrated. Various authors have suggested that occupational exposure to 
formaldehyde (present in paints, adhesives, cosmetics, textiles and tobacco smoke) is a possible risk 
factor.11-20  Ultraviolet A (UVA) and ultraviolet B (UVB) radiation play an integral role in the pathogenesis 
of most cutaneous melanomas through a variety of mechanisms, including direct melanocyte DNA 
damage or stimulation of melanocyte cell division, suppression of cutaneous immunity and free radical 
synthesis.  
 
Patients with sinonasal melanoma are often asymptomatic in the initial stages of the disease. However, 
with tumour growth, presenting complaints include unilateral or bilateral nasal obstruction, epistaxis, 
rhinorrhoea, hyposmia, epiphora, frontal headaches and facial pain. Proptosis and ophthalmoplegia with 
diplopia signal orbital involvement. These are late symptoms with an average delay in presentation 
varying from 1 month to 2 years.21 Mucosal lesions are usually pigmented, although non-pigmented, 
amelanotic melanomas are also possible. Independent clinical predictors of poorer survival include 
advanced patient age, large tumours and the nodal status or presence of distant metastases at 
diagnosis.22-23 
Thorough history taking, and clinical examination are important in the workup of sinonasal masses. The 
macroscopic appearance of sinonasal melanoma on anterior rhinoscopy or nasendoscopy varies from 
classical bluish-black mucosal lesions, to pale yellow or translucent polypoid masses in the amelanotic 
variant.24 Identifying the primary site often proves difficult as disease is usually widespread, sometimes 
with satellite lesions. Nodal assessment for regional disease (10-50% at presentation)25-26 and workup 
for distant metastases (40-76% at presentation27-28) are also important considerations. Thorough 
dermatological assessment for skin metastases is also required.25 
Histopathology with immunohistochemistry is the gold standard in confirming the diagnosis of sinonasal 
melanoma. Diagnosis based on histopathology alone can prove difficult and is prone to error.25  
Following histological confirmation of melanoma, various imaging modalities are employed to stage the 
disease. Computed tomography (CT) scanning usually demonstrates a soft tissue mass, with or without 
associated bony erosion. Magnetic resonance imaging (MRI) is useful in assessing tumour bulk and 
extent, especially orbital and intracranial involvement, as well as to differentiate between tumour mass 
and fluid/secretions within the sinuses.  Positron emission tomography (PET) scanning is a useful adjunct 
in assessing for distant metastases and local recurrence.11  
In 1970, Ballantyne described three stages of mucosal melanoma of the head and neck, based on 
tumour spread (local, regional and disseminated).29 The disadvantage of this staging system was that the 
extent of local disease and depth of invasion was not quantified. To overcome these shortcomings, 
Parsad et al.30 modified the Ballantyne staging system in 2004 to include 3 subgroups of stage I disease, 
taking depth of invasion into account. This sub-classification never gained universal acceptance and 
failed to correlate with prognosis in various studies.31 
The American Joint Committee on Cancer (AJCC) published a TNM staging system for mucosal 
melanoma in 2002, revised in 2009 (unchanged 2017) to reflect the aggressive behavior of these 
tumours. The 2009 system, proposed by Patel and Shah,32 is a specific classification for mucosal 
melanoma of the head and neck and depends on tumour size and extent. If the mucosal lesion is 
identified clinically, tumour stage will be at least T3. As such, T1 and T2 tumours cannot be identified 
clinically. In 2016, Houette et al.33 compared the prognostic value of the 2002 and 2009 TNM staging 
systems. The 2009 staging system allows for more homogenous patient groups and clearly distinguishes 
moderately advanced T3 disease from very advanced T4 disease, with a very poor prognosis. The non-
specific AJCC 2002 Clinical Staging Manual has better prognostic value, however, and the authors 
conclude that this system should not be abandoned. 
Literature guiding the management of sinonasal melanoma is limited to retrospective case series, 
precluding a robust assessment of outcomes. Best current practice is evolving and incorporates surgical 
resection, external beam radiotherapy (EBRT), chemotherapy, immunotherapy and targeted therapy in 
various combinations. Oncological outcomes of endonasal endoscopic resection and open resection are 
comparable.34 The role of adjuvant therapy, however, remains controversial. Despite sinonasal 
melanoma having the reputation of being a radioresistant tumour, the addition of adjuvant EBRT has 
recently been shown to improve local control rates and has become the standard of care.7,35-37 Chemo- 
and immunotherapy may improve survival but are not routinely administered and are associated with 
significant morbidity.38-40 Therapies targeting the specific gene mutations common to mucosal 
melanoma are currently being investigated in clinical trials and may contribute to management of 
sinonasal melanoma in the future.  
The authors’ unit has previously reported on the use of brachytherapy in the management of sinonasal 
melanoma.41 To our knowledge, this is the only case series on the matter in the literature. 
Materials and methods  
Ethics approval was obtained from the University of Cape Town Human Research Ethics Committee. 
Patients with sinonasal melanoma, undergoing endoscopic resection (DL single surgeon) and adjuvant 
brachytherapy between August 2004 and May 2014, were identified from an oncology database. Five 
patients were included in the series (Table 1). All patients underwent imaging (CT scan and MRI) 
following diagnosis. Tumours were staged according to the AJCC TNM staging system for mucosal 
melanoma (2009).32  
 
Following endoscopic tumour resection, brachytherapy was administered to the nasal cavities via an 
applicator. In all but one case, a 3mm silicone sheet was cut to match the contour of the nasal cavity and 
plastic tubes containing Iridium-192 were glued to the surface of the silicone applicator (Figure 1). Dose 
was measured 5mm from the surface of the implant (51-55 Gy in 51-100 hours). In one case, a 24 carat 
gold applicator with surface Iodine-125 seeds was used (60 Gy in 105 hours, measured at 2mm from the 
surface of the applicator).  
 
Patients were followed up with regular flexible nasendoscopy, with the addition of positron emission 
tomography (PET) scanning at time of diagnosis and on follow-up to assess for local recurrence and 
distant metastasis. Follow up CT/MRI scans were requested if suspicious lesions were identified 
clinically/endoscopically or on PET-CT. Lesions clinically and/or radiologically suspicious of recurrence 
were biopsied. 
 
A retrospective analysis of outcomes was carried out. Outcome measures included local control rate and 
5-year overall survival estimated by Kaplan-Meier analysis. The incidence of regional and distal 
recurrence (metastases) was calculated. Analyses were conducted using STATA statistical software 
(v13.0, StataCorp LLC, TX, USA).             
                                          
 
Figure 1: Silicone sheet glued with plastic tubes filled with Iridium 192 
Results  
Five cases of sinonasal melanoma (3 males, 2 females) were managed with endoscopic resection and 
adjuvant brachytherapy over a 10-year period (Table 1). Patient age ranged from 30 to 73 years (median 
57 years). Epistaxis was the presenting complaint in four out of five cases. One case presented with 
unilateral nasal obstruction. Local disease was staged as T4b in three cases, T4a in one case and T3 in 
one case at initial diagnosis. All cases were staged as N0M0 at diagnosis. Two patients had previously 
undergone endoscopic surgical resection of sinonasal melanoma, one with incomplete resection (T4a) 
and the other with local recurrence following resection and conventional radiotherapy (T4b).  
 
Patient  1 2 3 4 5 Summary 
Age at 
presentation  
30 years 46 years 57 years 70 years 73 years Median age            
57 (30 – 73) 
Gender  Male  Female  Female  Male  Male  3 Males; 2 
females 
Comorbidities  Skin melanoma 
excised 2008 
Hyper-
thyroidism  
Colon cancer 
(resected 
2015) 
Hypertension; 
ischemic heart 
disease 
(myocardial 
infarction 
2013) 
Ischemic heart 
disease 
 
Clinical 
presentation  
July 2012:  
Epistaxis; 
offensive 
rhinorrhea;  
postnasal drip 
 
August 2004: 
Epistaxis  
 
January 2013: 
Epistaxis; 
bloody 
rhinorrhea 
April 2008: 
Epistaxis 
 
May 2014: 
Left nasal 
obstruction  
4 out of 5 had 
epistaxis 
Stage  T3N0M0 T4bN0M0 T4aN0M0 T4bN0M0 T4bN0M0 1 was T3N0M0 
Previous surgery None  None Incomplete 
resection  
Multiple 
surgical 
resections 
None  2 had surgery 
before 
Surgery dates August 2012 December 
2005 
March 2013 February 2011 December 
2014; October 
2015; June 
2017 
 
Complications  None Cerebrospinal 
fluid (CSF), 
immediate 
repair  
Nasal crusting   None  Massive 
epistaxis   
 
Adjuvant 
brachytherapy  
October 2012:  
59 Gy/100hr 
December 
2005: 60 Gy/ 
105hr  
May 2013: 
55 Gy/100hr 
April 2011: 
54.6 Gy/78hr 
March 2015: 
51 Gy/ 51 Hr  
 
BRAF Positive  Not tested  Negative  Negative  Positive   
Follow up 
imaging 
CT, MRI, PET-
CT 
CT, MRI PET-
CT, US 
CT, MRI, PET 
CT 
CT, MRI, PET-
CT 
CT, MRI, PET- 
CT 
 
Local control Yes 
72 months 
Yes  
154 months  
Yes  
61 months 
Yes 
32 months  
No 
recurrence 
after 7 months  
 
Distant 
metastasis 
No 
72 months   
No  
154 months 
After 54 
months. Spinal 
metastasis  
After 15 
months 
Multiple 
abdominal 
metastasis 
After 24 
months. Bone 
metastasis 
(Hips, Pelvis, 
Humerus and 
Sternum)   
2 had no 
metastases 
Survival 
following 
treatment  
72  
months 
154 months 61 months  32 months  41 months  
Table 1: Patients undergoing endoscopic resection of sinonasal melanoma, followed by adjuvant 
brachytherapy 
Local control  
Local control was achieved in four out of five patients (80%) undergoing endoscopic surgical resection of 
sinonasal melanoma followed by adjuvant brachytherapy (Figure 2). Patients were followed up for a 
median duration of 61 months (32-154 months) following adjuvant brachytherapy. One patient 
developed local recurrence of disease 7 months following adjuvant Brachytherapy after primary 
resection and again at 14 months following secondary resection. Median disease-free duration was 61 
months (range 7-154 months). 
 
 
Figure 2: Kaplan-Meier estimates for local control  
Metastasis 
Three out of five patients developed distant metastasis. Median time to metastasis following adjuvant 
Brachytherapy was 54 months (range 15-154 months).  (Figure 3). One patient received immunotherapy 
after diagnosis of distant metastasis (BRAF positive). 
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Figure 3: Kaplan-Meier estimate for time to metastasis 
Survival 
Three out of five patients (60%) died from the complications of distant metastases of sinonasal 
melanoma. Median survival time following adjuvant Brachytherapy was 61 months (32-154 months). 
Five-year survival rate was 40% (95% CI 5.2% - 75.3%) (Figure 4). 
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 Figure 4: Kaplan-Meier estimate of overall survival during the follow up period 
Complications following endoscopic resection and adjuvant brachytherapy   
One patient developed a CSF leak during endoscopic resection of sinonasal melanoma as the dura mater 
was infiltrated with tumour. The leak was repaired immediately. One patient developed minimum nasal 
crusting postoperatively and another required blood transfusion following severe postoperative 
epistaxis immediately after surgery.        
Discussion     
Brachytherapy is an effective local treatment for select head and neck cancers, delivering high-dose 
radiation to a limited tissue volume, while sparing normal surrounding structures through steep dose 
reduction. Local tumour control rates are generally good and the side effect profile is preferable to that 
of EBRT.42,43 Brachytherapy has applications as both a primary and adjuvant form of treatment in the 
context of malignant head and neck tumours. It can also be used in cases of tumour recurrence in a 
previously irradiated site and in combination with EBRT to offer a radiation dose boost.44 
 
A study by Stannard et al. at our institution describes nine patients with minor salivary gland tumours of 
the soft and/or hard plate with positive resection margins or unfavorable histopathology, managed with 
adjuvant Iodine-125 Brachytherapy seed implants postoperatively. Implants were well tolerated, 
delivering a median dose of 65 Gy over a median duration of 120 hours. No local or regional recurrences 
were reported after a median follow up of 50 months.45 The same author reported on 114 patients with 
oral cavity/oropharynx squamous cell carcinoma managed with Iodine-125 brachytherapy following 
tumour resection. Median doses of 59.2 Gy and 22.7 Gy were administered without concurrent EBRT or 
as a dose boost together with EBRT respectively Local tumour control rates were 80.7% at 5 years and 
80% at 10 years. Brachytherapy was also found to be a cost-effective intervention as it is considerably 
less expensive than a course EBRT. 46  
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To our knowledge, Harris, et al.41 (at our institution) were the first to report on the use of postoperative 
brachytherapy in an attempt to reduce local recurrence after endoscopic resection of sinonasal 
melanoma. Kadah et al.47 published their experience with silicone brachytherapy applicators in 20 
patients with a spectrum of sinonasal and nasopharyngeal cancers after endoscopic tumour resection. 
Only one patient in the study had mucosal melanoma. Tumour control was achieved in 13 patients, 
seven patients experienced local recurrence and the overall 2-year survival was 57.3%. Their 
recommendation was that larger patient numbers were required to assess the efficacy of this method. 
Tselis et al.48 published their experience in treating four cases of inoperable, recurrent head and neck 
cancer with CT-guided interstitial high-dose rate brachytherapy. This included one patient with sinonasal 
melanoma, a 52-year-old male with T3N0M0 (AJCC 2009) disease. Initially treated with maxillofacial 
resection and adjuvant immunotherapy, he developed irresectable local recurrence after 4 months and 
was treated with chemoradiotherapy. Despite this, he presented with disease progression after six 
months. This patient then received brachytherapy and local control was achieved for a total of 31 
months thereafter.  
Our cases had a special brachytherapy applicator inserted and removed from the nasal cavities under 
general anesthesia, with simultaneous biopsy of any suspicious lesions identified. Radiation doses 
ranged from 51 to 60 Gy over 51 to 105 hours. Similar doses of intensity-modulated radiation therapy 
are usually delivered over a period of six weeks. Brachytherapy was well tolerated and no side-effects 
were reported.  Despite encouraging local control rates and overall survival, our retrospective case 
series comprised only five patients. Further studies are required to define the role of brachytherapy in 
the context of sinonasal melanoma. 
Despite aggressive surgical treatment of sinonasal melanoma and the addition of adjuvant radiotherapy, 
local recurrence rates reported in the literature range from 29-79%.52-53,39,54-56  In our small series of 
patients receiving adjuvant brachytherapy, local recurrence occurred in just one of five cases (20%). 
Local control was achieved in 80% of cases at a median follow up period of 61 months.  
Current management of sinonasal melanoma is associated with a 5-year survival of 0-46%.9 Our 5-year 
survival of 40% compares favorably with the literature. Kadah et al. reported an overall 2-year survival of 
57.3% after surgery and post-operative brachytherapy in the context of different sinonasal 
malignancies.47 Our 2-year survival rate was 100%. In keeping with the findings of Konuthula et al. 
Patients who developed distant metastasis had a poorer prognosis. 23 Other factors independently 
predicting poorer survival include advanced patient age, large tumours, regional metastasis and the 
histological findings of vascular invasion, necrosis and polymorphous tumour cell populations. 22-23,57, 49 
 
The management of sinonasal melanoma remains controversial and continues to evolve. Treatment 
options are discussed below.  
 
Surgery 
Complete resection is a surgical challenge and it is often impossible to achieve adequate margins due to 
tumour extent and the fact that tumour often abuts vital anatomical structures. Incomplete resection 
has been shown to be a predictor of poor survival.50-51,23 Surgical resection is occasionally considered 
following a course of neo-adjuvant radiation therapy or chemotherapy, when the tumour has more 
favorable dimensions and surgery is more likely to achieve adequate surgical margins.  
Surgical options for local control include endoscopic resection without dural excision, endoscopic 
resection with transnasal craniectomy, combined cranio-endoscopic resection and trans-facial external 
approaches.4 Outcome after endoscopic resection has been found to be comparable or better than the 
more aggressive external craniofacial approaches. The most important surgical prognostic factor is the 
presence of clear surgical margins.34 
In the N0 neck, prophylactic neck dissection is not indicated as the incidence of occult nodal metastasis 
is low (<10%). However, regional lymph node metastasis is associated with very high mortality rate.35  
Konuthula et al. analyzed the outcomes of patients with sinonasal melanoma registered on the 
American National Cancer Data Base (NCDB). In their analysis of 695 patients between 2004 and 2010, 
they found no statistically significant difference in 5-year survival between those managed with neck 
dissection and those managed without.23  
EBRT 
Historically, sinonasal melanoma was regarded as a radio-resistant tumour. Recently, however, studies 
have suggested that radiotherapy may improve local control, with little effect on overall survival.  No 
randomized controlled trial has been done in this regard. 7,35-37   
Systemic treatment 
A number of gene mutations (CDKN2A, RB1, CDK4, BRAF, KIT, NRAS) have been implicated in both the 
sporadic and hereditary variants of melanoma. Roughly 40% of cutaneous melanomas and 10-20% of 
mucosal melanomas.58  exhibit activating mutations responsible for structural changes in the BRAF 
protein, responsible for intracellular cell signaling and ultimately cell division and differentiation. The 
frequency of different gene mutations varies between cutaneous and sinonasal melanoma, and site of 
melanoma.59-63 Those mutations linked to UV radiation occur less frequently in the sinonasal variant, 
supporting the distinct nature and aetiology of sinonasal melanomas (which is unlikely to be related to 
sun exposure). In BRAF-mutant melanoma, targeted therapy (combining BRAF-inhibitors and 
immunotherapy) can target the BRAF driver mutation in tumour cells and sensitize the immune system 
to target tumour. Studies investigating targeted therapy have shown encouraging results, even 
suggested the potential for long-term control in advanced and metastatic disease.64 
Unlike cutaneous melanoma, sinonasal melanoma has a poor response to systemic treatment with 
either chemotherapy (mainly cisplatin and actinomycin D) or biochemotherapy (based on a 
biotherapeutic agent e.g. interferon, interleukin-2). Chemotherapy is most commonly used in the setting 
of palliative treatment or in cases where surgery is contraindicated.38-39 A meta-analysis of 39 studies 
showed no significant effect on overall survival by adding postoperative radiotherapy, but that survival 
was improved with the addition of adjuvant chemotherapy.40  
 
One patient in our series received systemic immunotherapy for BRAF-mutant sinonasal melanoma with 
systemic metastasis. A number of immunotherapeutic agents have been developed and are 
administered in various regimens, either as a single agent or in combination. A 2018 case report by 
Philipp et al. described their experience managing a case of c-KIT and BRAF positive sinonasal melanoma 
with advanced local recurrence and cervical lymph node metastasis after surgery, post-operative 
radiotherapy and low dose interferon. Complete resolution of disease was achieved with combined 
immunotherapy (ipilimumab and nivolumab).65 A pooled analysis by D’Angelo et al. suggested improved 
efficacy of combination therapy (nivolumab plus ipilimumab) compared to either agent administered 
alone.66 
 
Conclusion  
Sinonasal melanomas are rare, aggressive tumours with an unpredictable response to treatment and a 
poor prognosis. Diagnosis is usually followed by aggressive multimodal management in an attempt to 
achieve local control and improve outcomes. Maximal therapy usually entails surgical resection and 
adjuvant radiotherapy, with the roles of chemotherapy, immunotherapy and targeted therapies 
evolving. To our knowledge, this is the only case series describing the use of brachytherapy following 
endoscopic resection of sinonasal melanoma. Our case series, albeit small, describes a local control rate 
and 5-year survival comparable with the best reported in the literature. Adjuvant brachytherapy 
represents a novel approach and potentially a useful addition to the adjuvant therapy armamentarium. 
The advantages of brachytherapy include a favourable side-effect profile and a shorter duration of 
treatment, while delivering a dose of radiation similar to that of conventional radiotherapy. Further 
studies are necessary to define the role of brachytherapy in sinonasal melanoma. 
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